Introduction & Objective: A 16-week open-label study (NCT05114590) using blinded continuous glucose monitoring in insulin-naive adults with type 2 diabetes suboptimally controlled on ≥2 oral antihyperglycemic drugs (OADs) ± glucagon-like peptide-1 agonist (GLP-1 RA) showed that once daily iGlarLixi significantly increased TIR (26.2%; P<0.001). We describe patient-reported treatment satisfaction.
Methods: Treatment satisfaction was assessed with the Diabetes Medication Treatment Satisfaction Tool (DM-SAT), a 16-item survey scored from 0 (not at all) to 10 (extremely satisfied) in 4 domains. Association of TIR and overall satisfaction (sum of all items) was also assessed.
Results: In total, 124 people (58.9% males; 70.2% Hispanic/Latino; mean age 55.6 y, A1C 10.2%) were enrolled. At Week 16, there was improvement in overall and all subdomain scores (Table). For individual items, improvement was high for glucose control (+2.9), avoiding glucose highs (+2.7), and feeling in control of diabetes (+2.7). Treatment satisfaction was positively correlated with TIR (r 0.142; 95% CI -0.057, 0.328).
Conclusion: In people with type 2 diabetes suboptimally controlled on ≥2 OADs ± GLP-1 RA, 16 weeks’ treatment with iGlarLixi significantly improved treatment satisfaction, which may be associated with increased TIR.
V.N. Shah: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi, Medscape. Consultant; embecta, Tandem Diabetes Care, Inc. T.A. Dex: Stock/Shareholder; Pfizer Inc. Employee; Sanofi. Stock/Shareholder; Viatris Inc., Teva Pharmaceutical Industries Ltd. L. Meneghini: Employee; Sanofi. A. Rodrigues: Consultant; Sanofi. W.H. Polonsky: Research Support; Abbott Diagnostics, Dexcom, Inc. Consultant; Eli Lilly and Company, Sanofi. Advisory Panel; embecta. Consultant; Vertex Pharmaceuticals Incorporated. Advisory Panel; 9am Health.
Sanofi US
